Safe Bay 3389934がどのように適切か、適切な用量であり、敗血症誘発性凝固障害で参加者にどのように影響するかについて学ぶための研究
最初に患者では、用量のエスカレーション、安全性、忍容性、薬物動態、および敗血症誘発凝固障害患者に対するBAY 3389934の静脈内注入の薬力学を調査するためのオープンラベル研究
Researchers are looking for a better way to treat people who have sepsis induced coagulopathy.
Sepsis happens when bacteria and their toxins spread in the blood, causing an infection. To overcome the infection the body responds activating the immune system, sometimes this immune response is too active and causes uncontrolled blood clot formation, also called sepsis-induced coagulopathy. Sepsis coagulopathy damages blood vessels and organs and leads to low platelet levels in the body. In severe cases, it can even lead to death.
The main purpose of this first in patient study is to learn about how safe BAY 3389934 is, its suitable dose, and how it affects the participants with sepsis induced coagulopathy. For this study, researchers will enroll people receiving treatment for sepsis induced coagulopathy in a hospital intensive care unit (ICU).
For this, the researchers will collect the number of participants with medical problems during and after receiving BAY 3389934. These medical problems are also known as "adverse events". Doctors keep track of all medical problems that happen in studies, even if they do not think they might be related to the study treatments.
Participants will be divided into 2 groups. The first group will receive the lowest starting dose of BAY3389934. The researcher will carefully monitor how the participant responds to the medication and may adjust the dose, either increasing or decreasing it based on the safety and the tolerability of the drug. If no serious side effects are reported from the first group, the second group will receive higher dose of BAY3389934.
Each participant will be in the study for around 28 days. During the study, the doctors and their study team will:
- Take blood and urine samples,
- Do physical examinations,
- Check vital signs such as body temperature, blood pressure and heart rate,
- Examine heart health using electrocardiogram (ECG)
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Bayer Clinical Trials Contact
- 電話番号:188884229
- メール:clinical-trials-contact@bayer.com
研究場所
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- まだ募集していません
- UC Health University of Colorado Hospital - Medical Intensive Care Unit
-
-
-
-
Gelderland
-
Nijmegen、Gelderland、オランダ、6525 GA
- まだ募集していません
- Universitair Medisch Centrum St. Radboud - Intensive Care
-
Nijmegen、Gelderland、オランダ、6532 SZ
- まだ募集していません
- Canisius WIlhelmina Ziekenhuis - Intensive Care
-
-
North Brabant
-
's-Hertogenbosch、North Brabant、オランダ、5223 GZ
- まだ募集していません
- Jeroen Bosch Ziekenhuis - Intensive Care
-
-
Overijssel
-
Enschede、Overijssel、オランダ、7512 KZ
- まだ募集していません
- Medisch Spectrum Twente - Intensive Care
-
-
South Holland
-
Rotterdam、South Holland、オランダ、3015 GD
- まだ募集していません
- Erasmus Medisch Centrum - Intensive Care
-
-
-
-
Bavaria
-
München、Bavaria、ドイツ、81377
- まだ募集していません
- Klinikum der Universität München AöR - Klinik für Anaesthesiologie (Campus Großhadern)
-
-
North Rhine-Westphalia
-
Cologne、North Rhine-Westphalia、ドイツ、51109
- まだ募集していません
- Kliniken der Stadt Köln gGmbH - Krankenhaus Merheim - Lungenklinik
-
-
Saxony
-
Dresden、Saxony、ドイツ、01307
- 募集
- Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden | Medizinische Klinik I - FB Haemostaseologie
-
Leipzig、Saxony、ドイツ、04103
- まだ募集していません
- Universitätsklinikum Leipzig AöR_Interdisziplinare Internistische Intensivmedizin
-
-
-
-
Centre-Val de Loire
-
Tours、Centre-Val de Loire、フランス、37044
- まだ募集していません
- CHRU de Tours - Hôpital Bretonneau - Médecine Intensive Réanimation
-
-
Grand Est
-
Strasbourg、Grand Est、フランス、67091
- 募集
- Hopitaux Universitaires de Strasbourg Nouvel Hopital Civil - Service de Médecine Intensive Réanimation
-
-
New Aquitaine
-
Limoges、New Aquitaine、フランス、87042
- 募集
- Centre Hospitalier Universitaire de Limoges Dupuytren 1 - Service de réanimation polyvalente
-
-
Pays de la Loire Region
-
Angers、Pays de la Loire Region、フランス、49100
- 募集
- Centre Hospitalier Universitaire d'Angers - Médecine Intensive Réanimation et Médecine Hyperbare
-
La Roche-sur-Yon、Pays de la Loire Region、フランス、85000
- 募集
- Centre Hospitalier Départemental Vendée - Service de réanimation polyvalente
-
Nantes、Pays de la Loire Region、フランス、44000
- 募集
- Hopital Hotel Dieu Nantes - Service de Médecine Intensive Réanimation
-
-
Île-de-France Region
-
Garches、Île-de-France Region、フランス、92380
- まだ募集していません
- Hôpital Raymond-Poincaré - Service de Médecine Intensive - Réanimation, Médecine Hyperbare
-
-
-
-
-
Liège、ベルギー、4000
- 募集
- Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Intensive Care
-
-
Antwerp
-
Edegem、Antwerp、ベルギー、2650
- まだ募集していません
- UZ Antwerpen - Intensive Care
-
-
Brussels Capital
-
Woluwe-Saint-Lambert、Brussels Capital、ベルギー、1200
- まだ募集していません
- Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc - Intensive Care
-
-
Walloon Brabant
-
Ottignies、Walloon Brabant、ベルギー、1340
- 募集
- Clinique Saint-Pierre d'Ottignies - Intensive Care
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participant must be ≥ 18 and ≤ 85 years of age at the time of signing the informed consent.
- Participants with diagnosed sepsis according to sepsis-3 criteria. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.
- participants with suspected or documented origin of infection.
- Participants with coagulopathy defined by at least one of the following within 24 hours prior start of study intervention: INR ≥1.40, platelet count in the range of ≥ 30,000/mm3 to < 150,000/mm3 OR greater than 30% decrease in platelets in 24 hours without other known etiology. The platelet count after decrease should not be < 30,000/mm3.
- Participants must be receiving treatment in an ICU.
- Informed consent of capable participant or, in case of participant being incapable of giving informed consent, consent for study inclusion will be sought according to applicable laws and regulations.
Exclusion Criteria:
-
Clinically significant active bleeding; known bleeding disorder, history of major traumatic or non-traumatic bleeding (intracranial, retroperitoneal, intraocular) or clinically significant gastrointestinal bleeding within last 6 months.
-
Low platelets level or abnormal coagulation status due to any other reason than sepsis.
-
Participants with indication for therapeutic dose of: anticoagulation (heparin, argatroban, vitamin K antagonists/warfarin, dabigatran, apixaban, rivaroxaban, edoxaban), oral antiplatelet agents (clopidogrel, ticagrelor, ticlopidine, prasugrel) except low dose (≤100mg) acetyl salicylic acid (ASA), digoxin, metformin
-
Participants with:
- Uncontrolled malignancy requiring ongoing chemotherapy, radiation therapy, or immunotherapy within the past 6 months with the exception of: low-risk localized prostate cancer (Gleason score is equal to or less than 6 AND Prostate- Specific Antigen is below 10 ng/mL); or cervical carcinoma in situ; or ductal carcinoma in situ; or adequately treated non-metastatic squamous cell skin carcinoma; or adequately treated basal cell skin carcinoma. Patients with breast or prostate cancer receiving single endocrine (hormonal) therapy are eligible if all other cancer-directed treatments were completed more than 6 months prior to screening
- Any hematological malignancy
- Any active or prior malignancy involving the central nervous system (brain or spinal cord), including primary tumors or metastases.
-
Pregnancy or breastfeeding.
-
Chronic liver disease Child-Pugh Class C.
-
Participants experienced major surgery or major trauma (intrathoracic, intra-abdominal, pelvic or femur) or surgery/trauma in any other area with potentially clinically significant consequences due to bleeding within 28 days before study drug administration.
-
Participants experienced neurotrauma or neurosurgery (brain, spine) or orthopedic surgery in spine within 6 months before study drug administration
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Cohort 1 of BAY3389934
Subjects will receive titrated dose of BAY3389934 as continuous infusion over up to 96 hours. |
Solution for IV infusion |
|
実験的:Cohort 2 of BAY3389934
Subjects will receive titrated dose of BAY3389934 as continuous infusion over up to 96 hours. |
Solution for IV infusion |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
TEAESの参加者の数(治療に及ぶ有害事象)
時間枠:研究介入から1時間後に研究介入を最初に投与した後、97時間まで
|
研究介入から1時間後に研究介入を最初に投与した後、97時間まで
|
|
茶の重症度
時間枠:研究介入から1時間後に研究介入を最初に投与した後、97時間まで
|
研究介入から1時間後に研究介入を最初に投与した後、97時間まで
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
活性化された部分トロンボプラスチン時間(APTT)
時間枠:研究介入の最初の管理1日目から6日目まで
|
研究介入の最初の管理1日目から6日目まで
|
|
プロトロンビン時間(PT)
時間枠:研究介入の最初の管理1日目から6日目まで
|
研究介入の最初の管理1日目から6日目まで
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 22265
- 2024-515635-30-00 (レジストリ識別子:CTIS (EU))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。